REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, September 14 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd (Nasdaq: ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today that Amir Avniel, Rosetta Genomics' CEO, will present at Maxim Group's Growth conference on Thursday, September 20, at 5:00 pm EDT at the Grand Hyatt Hotel in New York.

A live audio webcast of the presentation will be available on the "Investors" section of the company's website, http://www.RosettaGenomics.com. A replay of the presentation will be available for 30 days after the conference.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases. For more information please visit: http://www.rosettagenomics.com

    Contact: Media
             Alan Zachary
             T: +1-312-944-6784
             media@rosettagenomics.com

             Investors
             Juliane Snowden
             T: +1-212-213-0006
             investors@rosettagenomics.com



SOURCE  Rosetta Genomics Ltd
    -0-                   09/14/2007
    /CONTACT:  Contact: Media, Alan Zachary, T: +1-312-944-6784,
media@rosettagenomics.com; Investors, Juliane Snowden, T: +1-212-213-0006,
investors@rosettagenomics.com/
    (ROSG)

CO:  Rosetta Genomics Ltd
ST:  New Jersey, New York, Israel
IN:  FIN BIO HEA
SU:  CCA


UK
-- UKF039 --
4007 09/14/2007 10:29 EDT http://www.prnewswire.com